Gene Express signs licensing agreement with NeoGenomics

NeoGenomics will support Gene Express in its FDA validation of its lung cancer risk prediction and BCR/ABL tests. The agreements will also allow NeoGenomics to commercialize Gene Express diagnostic tests, validate future Gene Express technology to fulfill FDA requirements, and utilize Standardized Reverse Transcription Polymerase Chain Reaction (StaRT-PCR) for their own commercial activities. These agreements succeed in establishing a key validation and commercialization partnership between Gene Express and NeoGenomics, the companies said.

Jonathan Rowe, senior vice president of strategy and clinical innovation for Gene Express, stated: “This partnership allows Gene Express to fully develop and execute its innovative pipeline with a skilled partner that is able to provide comprehensive support from validation through to commercialization of our products.”

Robert Gasparini, president and chief scientific officer for NeoGenomics, stated: “Gene Express has developed advanced and innovative technologies to support the diagnosis, prognosis and therapeutic response monitoring of disease. NeoGenomics, through its clinical trials services division is excited to provide our expert assay validation, development and FDA submission services to Gene Express for their lung cancer risk prediction, BCR/ABL and pipeline products.”